{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:02:39Z","timestamp":1792202559526,"version":"4.4.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,5,12]],"date-time":"2014-05-12T00:00:00Z","timestamp":1399852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2014,5,12]],"date-time":"2014-05-12T00:00:00Z","timestamp":1399852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Obes"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1038\/ijo.2014.76","type":"journal-article","created":{"date-parts":[[2014,5,12]],"date-time":"2014-05-12T07:39:19Z","timestamp":1399880359000},"page":"121-129","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":190,"title":["Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients"],"prefix":"10.1038","volume":"39","author":[{"given":"J M","family":"Gallego-Escuredo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"G\u00f3mez-Ambrosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Catalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Domingo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Giralt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Fr\u00fchbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Villarroya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,5,12]]},"reference":[{"key":"BFijo201476_CR1","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1172\/JCI23606","volume":"115","author":"A Kharitonenkov","year":"2005","unstructured":"Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ et al. FGF-21 as a novel metabolic regulator. J Clin Invest 2005; 115: 1627\u20131635.","journal-title":"J Clin Invest"},{"key":"BFijo201476_CR2","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1210\/endo.143.5.8850","volume":"143","author":"E Tomlinson","year":"2002","unstructured":"Tomlinson E, Fu L, John L, Hultgren B, Huang X, Renz M et al. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 2002; 143: 1741\u20131747.","journal-title":"Endocrinology"},{"key":"BFijo201476_CR3","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0167-4781(00)00067-1","volume":"1492","author":"T Nishimura","year":"2000","unstructured":"Nishimura T, Nakatake Y, Konishi M, Itoh N . Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta 2000; 1492: 203\u2013206.","journal-title":"Biochim Biophys Acta"},{"key":"BFijo201476_CR4","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1053\/j.gastro.2010.04.054","volume":"139","author":"J Dushay","year":"2010","unstructured":"Dushay J, Chui PC, Gopalakrishnan GS, Varela-Rey M, Crawley M, Fisher FM et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 2010; 139: 456\u2013463.","journal-title":"Gastroenterology"},{"key":"BFijo201476_CR5","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.2337\/db08-1775","volume":"58","author":"K Mai","year":"2009","unstructured":"Mai K, Andres J, Biedasek K, Weicht J, Bobbert T, Sabath M et al. Free fatty acids link metabolism and regulation of the insulin-sensitizing fibroblast growth factor-21. Diabetes 2009; 58: 1532\u20131538.","journal-title":"Diabetes"},{"key":"BFijo201476_CR6","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.cmet.2007.05.003","volume":"5","author":"T Inagaki","year":"2007","unstructured":"Inagaki T, Dutchak P, Zhao G, Ding X, Gautron L, Parameswara V et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab 2007; 5: 415\u2013425.","journal-title":"Cell Metab"},{"key":"BFijo201476_CR7","doi-asserted-by":"publisher","first-page":"250","DOI":"10.2337\/db08-0392","volume":"58","author":"J Xu","year":"2009","unstructured":"Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, Sivits G et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 2009; 58: 250\u2013259.","journal-title":"Diabetes"},{"key":"BFijo201476_CR8","doi-asserted-by":"publisher","first-page":"6018","DOI":"10.1210\/en.2008-0816","volume":"149","author":"T Coskun","year":"2008","unstructured":"Coskun T, Bina HA, Schneider MA, Dunbar JD, Hu CC, Chen Y et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 2008; 149: 6018\u20136027.","journal-title":"Endocrinology"},{"key":"BFijo201476_CR9","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/j.1365-2826.2012.02383.x","volume":"25","author":"M Murphy","year":"2013","unstructured":"Murphy M, Samms R, Warner A, Bolborea M, Barrett P, Fowler MJ et al. Increased responses to the actions of fibroblast growth factor 21 on energy balance and body weight in a seasonal model of adiposity. J Neuroendocrinol 2013; 25: 180\u2013189.","journal-title":"J Neuroendocrinol"},{"key":"BFijo201476_CR10","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1210\/en.2010-1262","volume":"153","author":"C Hale","year":"2012","unstructured":"Hale C, Chen MM, Stanislaus S, Chinookoswong N, Hager T, Wang M et al. Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance. Endocrinology 2012; 153: 69\u201380.","journal-title":"Endocrinology"},{"key":"BFijo201476_CR11","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.2337\/dc09-0684","volume":"32","author":"AO Chavez","year":"2009","unstructured":"Chavez AO, Molina-Carrion M, Abdul-Ghani MA, Folli F, DeFronzo RA, Tripathy D . Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care 2009; 32: 1542\u20131546.","journal-title":"Diabetes Care"},{"key":"BFijo201476_CR12","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.2337\/db07-1476","volume":"57","author":"X Zhang","year":"2008","unstructured":"Zhang X, Yeung DC, Karpisek M, Stejskal D, Zhou ZG, Liu F et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008; 57: 1246\u20131253.","journal-title":"Diabetes"},{"key":"BFijo201476_CR13","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.2337\/db10-0193","volume":"59","author":"FM Fisher","year":"2010","unstructured":"Fisher FM, Chui PC, Antonellis PJ, Bina HA, Kharitonenkov A, Flier JS et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 2010; 59: 2781\u20132789.","journal-title":"Diabetes"},{"key":"BFijo201476_CR14","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/dmrr.1177","volume":"27","author":"FL Mashili","year":"2011","unstructured":"Mashili FL, Austin RL, Deshmukh AS, Fritz T, Caidahl K, Bergdahl K et al. Direct effects of FGF21 on glucose uptake in human skeletal muscle: implications for type 2 diabetes and obesity. Diabetes Metab Res Rev 2011; 27: 286\u2013297.","journal-title":"Diabetes Metab Res Rev"},{"key":"BFijo201476_CR15","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.cmet.2013.08.005","volume":"18","author":"G Gaich","year":"2013","unstructured":"Gaich G, Chien JY, Fu H, Glass LC, Deeg MA, Holland WL et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab 2013; 18: 333\u2013340.","journal-title":"Cell Metab"},{"key":"BFijo201476_CR16","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2337\/dc12-0703","volume":"36","author":"T Bobbert","year":"2013","unstructured":"Bobbert T, Schwarz F, Fischer-Rosinsky A, Pfeiffer AF, Mohlig M, Mai K et al. Fibroblast growth factor 21 predicts the metabolic syndrome and type 2 diabetes in Caucasians. Diabetes Care 2013; 36: 145\u2013149.","journal-title":"Diabetes Care"},{"key":"BFijo201476_CR17","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.cmet.2005.09.001","volume":"2","author":"T Inagaki","year":"2005","unstructured":"Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005; 2: 217\u2013225.","journal-title":"Cell Metab"},{"key":"BFijo201476_CR18","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1210\/en.2003-1671","volume":"145","author":"L Fu","year":"2004","unstructured":"Fu L, John LM, Adams SH, Yu XX, Tomlinson E, Renz M et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 2004; 145: 2594\u20132603.","journal-title":"Endocrinology"},{"key":"BFijo201476_CR19","doi-asserted-by":"publisher","first-page":"10023","DOI":"10.1074\/jbc.M808818200","volume":"284","author":"S Bhatnagar","year":"2009","unstructured":"Bhatnagar S, Damron HA, Hillgartner FB . Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis. J Biol Chem 2009; 284: 10023\u201310033.","journal-title":"J Biol Chem"},{"key":"BFijo201476_CR20","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1126\/science.1198363","volume":"331","author":"S Kir","year":"2011","unstructured":"Kir S, Beddow SA, Samuel VT, Miller P, Previs SF, Suino-Powell K et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 2011; 331: 1621\u20131624.","journal-title":"Science"},{"key":"BFijo201476_CR21","doi-asserted-by":"publisher","first-page":"14379","DOI":"10.1073\/pnas.0907812106","volume":"106","author":"X Wu","year":"2009","unstructured":"Wu X, Ge H, Lemon B, Weiszmann J, Gupte J, Hawkins N et al. Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob\/ob mice. Proc Natl Acad Sci USA 2009; 106: 14379\u201314384.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFijo201476_CR22","doi-asserted-by":"crossref","first-page":"627","DOI":"10.33549\/physiolres.932099","volume":"60","author":"M Mraz","year":"2011","unstructured":"Mraz M, Lacinova Z, Kavalkova P, Haluzikova D, Trachta P, Drapalova J et al. Serum concentrations of fibroblast growth factor 19 in patients with obesity and type 2 diabetes mellitus: the influence of acute hyperinsulinemia, very-low calorie diet and PPAR-alpha agonist treatment. Physiol Res 2011; 60: 627\u2013636.","journal-title":"Physiol Res"},{"key":"BFijo201476_CR23","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.2337\/dc12-2255","volume":"36","author":"GS Gerhard","year":"2013","unstructured":"Gerhard GS, Styer AM, Wood GC, Roesch SL, Petrick AT, Gabrielsen J et al. A role for fibroblast growth factor 19 and bile acids in diabetes remission after Roux-en-Y gastric bypass. Diabetes Care 2013; 36: 1859\u20131864.","journal-title":"Diabetes Care"},{"key":"BFijo201476_CR24","unstructured":"Gallego-Escuredo JM, Gomez-Ambrosi J, Catalan V, Domingo P, Giralt M, Fruhbeck G et al. Alterations in the FGF19 hormone factor in obese patients. Effect of weight loss. Obes Rev 2011; 12 (Suppl 1): 217 (abstract p.115)."},{"key":"BFijo201476_CR25","doi-asserted-by":"publisher","first-page":"26687","DOI":"10.1074\/jbc.M704165200","volume":"282","author":"H Kurosu","year":"2007","unstructured":"Kurosu H, Choi M, Ogawa Y, Dickson AS, Goetz R, Eliseenkova AV et al. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem 2007; 282: 26687\u201326695.","journal-title":"J Biol Chem"},{"key":"BFijo201476_CR26","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.18632\/aging.100108","volume":"1","author":"X Wu","year":"2009","unstructured":"Wu X, Li Y . Role of FGF19 induced FGFR4 activation in the regulation of glucose homeostasis. Aging (Albany NY) 2009; 1: 1023\u20131027.","journal-title":"Aging (Albany NY)"},{"key":"BFijo201476_CR27","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1210\/me.2007-0313","volume":"22","author":"M Suzuki","year":"2008","unstructured":"Suzuki M, Uehara Y, Motomura-Matsuzaka K, Oki J, Koyama Y, Kimura M et al. betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Mol Endocrinol 2008; 22: 1006\u20131014.","journal-title":"Mol Endocrinol"},{"key":"BFijo201476_CR28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/978-1-4614-0887-1_2","volume":"728","author":"M Kuro-o","year":"2012","unstructured":"Kuro-o M . Klotho and betaKlotho. Adv Exp Med Biol 2012; 728: 25\u201340.","journal-title":"Adv Exp Med Biol"},{"key":"BFijo201476_CR29","doi-asserted-by":"publisher","first-page":"7432","DOI":"10.1073\/pnas.0701600104","volume":"104","author":"Y Ogawa","year":"2007","unstructured":"Ogawa Y, Kurosu H, Yamamoto M, Nandi A, Rosenblatt KP, Goetz R et al. BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Proc Natl Acad Sci USA 2007; 104: 7432\u20137437.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFijo201476_CR30","doi-asserted-by":"publisher","first-page":"10853","DOI":"10.1073\/pnas.0904187106","volume":"106","author":"MJ Potthoff","year":"2009","unstructured":"Potthoff MJ, Inagaki T, Satapati S, Ding X, He T, Goetz R et al. FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc Natl Acad Sci USA 2009; 106: 10853\u201310858.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFijo201476_CR31","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1210\/en.2011-0281","volume":"152","author":"FM Fisher","year":"2011","unstructured":"Fisher FM, Estall JL, Adams AC, Antonellis PJ, Bina HA, Flier JS et al. Integrated regulation of hepatic metabolism by fibroblast growth factor 21 (FGF21) in vivo. Endocrinology 2011; 152: 2996\u20133004.","journal-title":"Endocrinology"},{"key":"BFijo201476_CR32","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.molmet.2012.08.007","volume":"2","author":"AC Adams","year":"2012","unstructured":"Adams AC, Yang C, Coskun T, Cheng CC, Gimeno RE, Luo Y et al. The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue. Mol Metab 2012; 2: 31\u201337.","journal-title":"Mol Metab"},{"key":"BFijo201476_CR33","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1038\/oby.2005.146","volume":"13","author":"SR Ginde","year":"2005","unstructured":"Ginde SR, Geliebter A, Rubiano F, Silva AM, Wang J, Heshka S et al. Air displacement plethysmography: validation in overweight and obese subjects. Obes Res 2005; 13: 1232\u20131237.","journal-title":"Obes Res"},{"key":"BFijo201476_CR34","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.2337\/diacare.26.12.3331","volume":"26","author":"S Genuth","year":"2003","unstructured":"Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26: 3160\u20133167.","journal-title":"Diabetes Care"},{"key":"BFijo201476_CR35","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1007\/s11695-008-9424-z","volume":"17","author":"V Catalan","year":"2007","unstructured":"Catalan V, Gomez-Ambrosi J, Ramirez B, Rotellar F, Pastor C, Silva C et al. Proinflammatory cytokines in obesity: impact of type 2 diabetes mellitus and gastric bypass. Obes Surg 2007; 17: 1464\u20131474.","journal-title":"Obes Surg"},{"key":"BFijo201476_CR36","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1381\/096089206776116525","volume":"16","author":"J Gomez-Ambrosi","year":"2006","unstructured":"Gomez-Ambrosi J, Salvador J, Rotellar F, Silva C, Catalan V, Rodriguez A et al. Increased serum amyloid A concentrations in morbid obesity decrease after gastric bypass. Obes Surg 2006; 16: 262\u2013269.","journal-title":"Obes Surg"},{"key":"BFijo201476_CR37","doi-asserted-by":"publisher","first-page":"3719","DOI":"10.1210\/jc.2007-0349","volume":"92","author":"J Gomez-Ambrosi","year":"2007","unstructured":"Gomez-Ambrosi J, Catalan V, Ramirez B, Rodriguez A, Colina I, Silva C et al. Plasma osteopontin levels and expression in adipose tissue are increased in obesity. J Clin Endocrinol Metab 2007; 92: 3719\u20133727.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFijo201476_CR38","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1093\/clinchem\/41.5.717","volume":"41","author":"H Sugiuchi","year":"1995","unstructured":"Sugiuchi H, Uji Y, Okabe H, Irie T, Uekama K, Kayahara N et al. Direct measurement of high-density lipoprotein cholesterol in serum with polyethylene glycol-modified enzymes and sulfated alpha-cyclodextrin. Clin Chem 1995; 41: 717\u2013723.","journal-title":"Clin Chem"},{"key":"BFijo201476_CR39","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1097\/QAD.0b013e3283400088","volume":"24","author":"P Domingo","year":"2010","unstructured":"Domingo P, Gallego-Escuredo JM, Domingo JC, Gutierrez MM, Mateo MG, Fernandez I et al. Serum FGF21 levels are elevated in association with lipodystrophy, insulin resistance and biomarkers of liver injury in HIV-1-infected patients. AIDS 2010; 24: 2629\u20132637.","journal-title":"AIDS"},{"key":"BFijo201476_CR40","doi-asserted-by":"publisher","first-page":"84","DOI":"10.2144\/04361ST04","volume":"36","author":"JL Aerts","year":"2004","unstructured":"Aerts JL, Gonzales MI, Topalian SL . Selection of appropriate control genes to assess expression of tumor antigens using real-time RT-PCR. Biotechniques 2004; 36: 84\u20131.","journal-title":"Biotechniques"},{"key":"BFijo201476_CR41","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/oby.2002.83","volume":"10","author":"BG Gabrielsson","year":"2002","unstructured":"Gabrielsson BG, Johansson JM, Jennische E, Jernas M, Itoh Y, Peltonen M et al. Depot-specific expression of fibroblast growth factors in human adipose tissue. Obes Res 2002; 10: 608\u2013616.","journal-title":"Obes Res"},{"key":"BFijo201476_CR42","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1021\/mp700105z","volume":"5","author":"S Jones","year":"2008","unstructured":"Jones S . Mini-review: endocrine actions of fibroblast growth factor 19. Mol Pharm 2008; 5: 42\u201348.","journal-title":"Mol Pharm"},{"key":"BFijo201476_CR43","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1475-2891-10-70","volume":"10","author":"VP Sakamuri","year":"2011","unstructured":"Sakamuri VP, Ananthathmakula P, Veettil GN, Ayyalasomayajula V . Vitamin A decreases pre-receptor amplification of glucocorticoids in obesity: study on the effect of vitamin A on 11beta-hydroxysteroid dehydrogenase type 1 activity in liver and visceral fat of WNIN\/Ob obese rats. Nutr J 2011; 10: 70.","journal-title":"Nutr J"},{"key":"BFijo201476_CR44","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.metabol.2010.02.016","volume":"60","author":"K Mai","year":"2011","unstructured":"Mai K, Schwarz F, Bobbert T, Andres J, Assmann A, Pfeiffer AF et al. Relation between fibroblast growth factor-21, adiposity, metabolism, and weight reduction. Metabolism 2011; 60: 306\u2013311.","journal-title":"Metabolism"},{"key":"BFijo201476_CR45","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1038\/ijo.2013.10","volume":"37","author":"M Straczkowski","year":"2013","unstructured":"Straczkowski M, Karczewska-Kupczewska M, Adamska A, Otziomek E, Kowalska I, Nikolajuk A . Serum fibroblast growth factor 21 in human obesity: regulation by insulin infusion and relationship with glucose and lipid oxidation. Int J Obes (Lond) 2013; 37: 1386\u20131390.","journal-title":"Int J Obes (Lond)"},{"key":"BFijo201476_CR46","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.2337\/dc11-0294","volume":"34","author":"C Chen","year":"2011","unstructured":"Chen C, Cheung BM, Tso AW, Wang Y, Law LS, Ong KL et al. High plasma level of fibroblast growth factor 21 is an Independent predictor of type 2 diabetes: a 5.4-year population-based prospective study in Chinese subjects. Diabetes Care 2011; 34: 2113\u20132115.","journal-title":"Diabetes Care"},{"key":"BFijo201476_CR47","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1097\/QAI.0b013e318271c2c7","volume":"61","author":"JM Gallego-Escuredo","year":"2012","unstructured":"Gallego-Escuredo JM, Domingo P, Gutierrez MM, Mateo MG, Cabeza MC, Fontanet A et al. Reduced levels of serum FGF19 and impaired expression of receptors for endocrine FGFs in adipose tissue from HIV-infected patients. J Acquir Immune Defic Syndr 2012; 61: 527\u2013534.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"BFijo201476_CR48","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.metabol.2013.11.014","volume":"63","author":"E Hondares","year":"2014","unstructured":"Hondares E, Gallego-Escuredo JM, Flachs P, Frontini A, Cereijo R, Goday A et al. Fibroblast growth factor-21 is expressed in neonatal and pheochromocytoma-induced adult human brown adipose tissue. Metabolism 2014; 63: 312\u2013317.","journal-title":"Metabolism"},{"key":"BFijo201476_CR49","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1210\/jc.2012-1221","volume":"97","author":"T Reinehr","year":"2012","unstructured":"Reinehr T, Woelfle J, Wunsch R, Roth CL . Fibroblast growth factor 21 (FGF-21) and its relation to obesity, metabolic syndrome, and nonalcoholic fatty liver in children: a longitudinal analysis. J Clin Endocrinol Metab 2012; 97: 2143\u20132150.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFijo201476_CR50","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.diabres.2011.02.034","volume":"93","author":"X Li","year":"2011","unstructured":"Li X, Fan X, Ren F, Zhang Y, Shen C, Ren G et al. Serum FGF21 levels are increased in newly diagnosed type 2 diabetes with nonalcoholic fatty liver disease and associated with hsCRP levels independently. Diabetes Res Clin Pract 2011; 93: 10\u201316.","journal-title":"Diabetes Res Clin Pract"},{"key":"BFijo201476_CR51","doi-asserted-by":"publisher","first-page":"E241","DOI":"10.1210\/jc.2013-3129","volume":"99","author":"GJ Morton","year":"2014","unstructured":"Morton GJ, Kaiyala KJ, Foster-Schubert KE, Cummings DE, Schwartz MW . Carbohydrate feeding dissociates the postprandial FGF19 response from circulating bile acid levels in humans. J Clin Endocrinol Metab 2014; 99: E241\u2013E245.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFijo201476_CR52","first-page":"220","volume":"64","author":"M Zhang","year":"2013","unstructured":"Zhang M, Liu Y, Xiong ZY, Deng ZY, Song HL, An ZM . Changes of plasma fibroblast growth factor-21 (FGF-21) in oral glucose tolerance test and effects of metformin on FGF-21 levels in type 2 diabetes mellitus. Endokrynol Pol 2013; 64: 220\u2013224.","journal-title":"Endokrynol Pol"},{"key":"BFijo201476_CR53","doi-asserted-by":"publisher","first-page":"4238","DOI":"10.1210\/en.2012-1193","volume":"153","author":"J Diaz-Delfin","year":"2012","unstructured":"Diaz-Delfin J, Hondares E, Iglesias R, Giralt M, Caelles C, Villarroya F . TNF-alpha represses beta-Klotho expression and impairs FGF21 action in adipose cells: involvement of JNK1 in the FGF21 pathway. Endocrinology 2012; 153: 4238\u20134245.","journal-title":"Endocrinology"},{"key":"BFijo201476_CR54","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/ijo.2013.79","volume":"38","author":"EB Nygaard","year":"2014","unstructured":"Nygaard EB, Moller CL, Kievit P, Grove KL, Andersen B . Increased fibroblast growth factor 21 expression in high-fat diet-sensitive non-human primates (Macaca mulatta). Int J Obes (Lond) 2014; 38: 183\u2013191.","journal-title":"Int J Obes (Lond)"},{"key":"BFijo201476_CR55","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.cmet.2012.08.002","volume":"16","author":"X Ding","year":"2012","unstructured":"Ding X, Boney-Montoya J, Owen BM, Bookout AL, Coate KC, Mangelsdorf DJ et al. betaKlotho is required for fibroblast growth factor 21 effects on growth and metabolism. Cell Metab 2012; 16: 387\u2013393.","journal-title":"Cell Metab"},{"key":"BFijo201476_CR56","doi-asserted-by":"publisher","first-page":"16137","DOI":"10.1073\/pnas.1205951109","volume":"109","author":"T Fu","year":"2012","unstructured":"Fu T, Choi SE, Kim DH, Seok S, Suino-Powell KM, Xu HE et al. Aberrantly elevated microRNA-34a in obesity attenuates hepatic responses to FGF19 by targeting a membrane coreceptor beta-Klotho. Proc Natl Acad Sci USA 2012; 109: 16137\u201316142.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFijo201476_CR57","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.tem.2010.11.003","volume":"22","author":"A Kharitonenkov","year":"2011","unstructured":"Kharitonenkov A, Larsen P . FGF21 reloaded: challenges of a rapidly growing field. Trends Endocrinol Metab 2011; 22: 81\u201386.","journal-title":"Trends Endocrinol Metab"}],"container-title":["International Journal of Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/ijo201476.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ijo201476","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ijo201476.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T19:05:08Z","timestamp":1647371108000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ijo201476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,12]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["BFijo201476"],"URL":"https:\/\/doi.org\/10.1038\/ijo.2014.76","relation":{},"ISSN":["0307-0565","1476-5497"],"issn-type":[{"value":"0307-0565","type":"print"},{"value":"1476-5497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,12]]},"assertion":[{"value":"30 January 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}